UT Health San Antonio, San Antonio, TX
Parth Anil Desai , Sushanth Kakarla , Annapurna Saksena , Byeongyeob Choi , Martin Goros , Frank R. Miller , Anand B. Karnad , Sherri Rauenzahn Cervantez
Background: Pre-treatment Body mass Index (BMI) is an important prognostic factor in HNC with variable survival benefit reported till date. Despite increasing incidence of HNC in geriatric patients there is limited information on prognostic variables in this group. Methods: This is a single center, retrospective cohort study of patients with HNC≥65 years of age at their diagnosis from 2012 to 2016. Patients were stratified by BMI (Class 1- BMI<25 kg/m2 (underweight & normal), Class 2- BMI≥25-29.9 kg/m2 (overweight), Class 3- BMI≥30 kg/m2 (obese) ). Various variables were collected & appropriate statistical analysis was done. Results: 188 elderly HNC patients with non-metastatic disease were stratified into three BMI groups (Table) & found to have evenly distributed co-variates. The Median OS was significantly higher in class 3 patients (53 months) compared to class 1 (21 months) (p =0.02). In multivariate analysis, class 3 was an independent good prognostic indicator (Hazard ratio=0.44;Range-0.21-0.90, p=0.03). Stage, CCI score & gastrostomy tube were adverse prognostic factors in the study. Conclusions: Obese elderly HNC patients have survival benefit over normal/underweight patients. Predictive prognostic models incorporating BMI with other prognostic factors are needed to determine appropriate management in these patients.
CHARACTERISTICS | Class 1 BMI <25 (78 patients) | Class 2 BMI 25-29.9 (67 patients) | Class 3 BMI ≥ 30 (43 patients) | p-value |
---|---|---|---|---|
MEAN AGE AT DIAGNOSIS (SD) Years | 75.12 (7.46) | 73.38 (6.13) | 73.96 (6.14) | 0.290 |
SEX (%) | ||||
WOMEN | 27 (34.6) | 16 (23.9) | 15 (34.9) | 0.305 |
MEN | 51 (65.4) | 51 (76.1) | 28 (65.1) | |
PATHOLOGICAL TYPE (%) | ||||
SCC | 71 (90.9) | 58 (86.6) | 36 (83.7) | 0.409 |
OTHERS | 8 (9.1) | 9 (13.4) | 7 (16.2) | |
TNM STAGE (%) | ||||
STAGE 1 | 5 (6.4) | 11 (16.4) | 8 (18.6) | 0.745 |
STAGE 2 | 13 (16.7) | 9 (13.4) | 9 (20.9) | |
STAGE 3 | 9 (11.5) | 7 (10.4) | 4 (9.3) | |
STAGE 4A | 34 (43.6) | 24 (35.8) | 13 (31.0) | |
STAGE 4B | 12 (15.3) | 11 (16.0) | 5 (11.6) | |
UNKNOWN | 5 (6.4) | 5 (7.5) | 4 (9.3) | |
CHARLSON COMORBIDITY INDEX (CCI) MEAN (SD) | ||||
INITIAL TREATMENT (%) | 5.03 (2.34) | 5.54 (2.92) | 5.28 (1.78) | 0.460 |
CHEMOTHERAPY ONLY | 5 (6.4) | 1 (1.5) | 2 (4.7) | 0.628 |
CHEMOTHERAPY + SURGERY | 0 (0.0) | 0 (0.0) | 1 (2.3) | |
CHEMORADIATION | 16 (20.5) | 13 (19.4) | 8 (18.6) | |
CHEMORADIATION + SURGERY | 6 (7.7) | 10 (14.9) | 5 (11.6) | |
RADIATION ONLY | 7 (9.0) | 9 (13.4) | 7 (16.3) | |
RADIATION +SURGERY | 8 (10.3) | 10 (14.9) | 7 (16.3) | |
SURGERY ONLY | 19 (24.4) | 14 (20.9) | 7 (16.3) | |
NONE/SUPPORTIVE ONLY/HOSPICE | 17 (21.8) | 10 (14.9) | 6 (14.0) | |
MEAN SURVIVAL TIME (SD) Days | 368.35 (353.9) | 527.08 (319.10) | 590.27 (495.62) | 0.080 |
DECEASED AT LAST FOLLOW-UP (%) | ||||
NO | 35 (44.9) | 42 (62.7) | 28 (65.1) | 0.037 |
YES | 43 (55.1) | 25 (37.3) | 15 (34.9) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Kazuki Watabe
2024 ASCO Annual Meeting
First Author: Sakditad Saowapa
2023 ASCO Annual Meeting
First Author: Anshu Hemrajani
2024 ASCO Annual Meeting
First Author: Zac Coyne